Sanofi Eloxatin
Executive Summary
FDA's Oncologic Drugs Advisory Committee will meet March 16 to evaluate oxaliplatin (NDA 21-063) for first-line treatment of patients with advanced colorectal cancer in combination with 5-FU. In the afternoon, the committee will discuss Pharmacia & Upjohn's Camptosar (irinotecan, NDA 20-571/SE1-009) for first-line treatment for patients with metastatic cancer of the colon or rectum